New Key Statistics Module, Z-Score and F-Score
NAS:CCCC Key Ratios
| Market Cap $ M | 321.18 |
| Enterprise Value $ M | 132.63 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 1.32 |
| Price/Sales | 9.05 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 33.00 |
| EPS (TTM) $ | -1.70 |
| Beneish M-Score | 8.34 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | 8.70 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -1.26 |
| EV-to-EBITDA | -1.28 |
| PEG | -- |
| Shares Outstanding M | 70.59 |
| Net Margin (%) | -313.35 |
| Operating Margin % | -347.20 |
| Pre-tax Margin (%) | -312.52 |
| Quick Ratio | 6.31 |
| Current Ratio | 6.31 |
| ROA % (ttm) | -28.28 |
| ROE % (ttm) | -43.59 |
| ROIC % (ttm) | -81.43 |
| Dividend Yield % | -- |
| Altman Z-Score | -0.89 |
CCCC Number of Guru Trades
CCCC Volume of Guru Trades
Gurus Latest Trades with NAS:CCCC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:CCCC is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
C4 Therapeutics Inc Insider Transactions
No Available Data
News about NAS:CCCC
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers